Karo Pharma AB (publ)
KARBF
Other OTC5.25
USD
- -
- -
Karo Pharma AB (publ)
KARBF
(Other OTC)
Recent
price
5.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Karo Pharma AB (publ) Karo Pharma AB (publ), now operating as Karo Healthcare AB, develops, owns, and commercializes branded over-the-counter consumer healthcare products and select prescription medicines that address everyday health needs, including prevention and treatment of common ailments. The company offers an extensive portfolio spanning key categories such as skin health with brands including E45, Remescar, Locobase, Decubal, and indy beauty; intimate health under Pevaryl, Multi-Gyn, Asan, and Selexid; digestive health via Scheriproct and Hemoproct; foot health through Pevaryl, Nailner, CCS, and Wortie; wellness products like Nutravita, Alpha Foods, Flux, Allévo, and Lactocare; pain, cough, and cold remedies such as Paracet, Ibux, Mollipect, and Viruseptin; and specialty products including Burinex, Centyl, Kaleorid, and Lithionit. These over 500 products reach consumers in more than 90 countries through pharmacies, retailers, digital channels, and healthcare providers, with core operations in Europe and the Nordic region where the company maintains its own sales organizations across more than 10 countries; Karo Healthcare employs approximately 460 people from over 40 nationalities across 13 countries and generates annual revenue exceeding €500 million. Founded in 1987 and headquartered in Stockholm, Sweden, the company targets individual consumers seeking self-care solutions alongside pharmacy and retail partners in the consumer health sector. In recent major developments, Karo Healthcare transitions to ownership by funds managed by KKR & Co. Inc. following the completion of its acquisition from EQT AB in August 2025 after an agreement announced in April 2025 valuing the business above €2.5 billion, capping a strategic transformation that quadrupled sales since 2019 through eight acquisitions and 150 new product launches by 2023; the company further strengthens its portfolio via a pending acquisition of Perrigo's Dermacosmetics business announced in July 2025 for closure in Q1 2026 adding over €120 million in annual sales from skincare brands in the Nordics, Netherlands, and Poland, alongside an exclusive licensing deal with Moberg Pharma AB for MOB-015 commercialization in 19 European markets and the appointment of Konstanze Gallinatus as Chief Transformation Officer to support ongoing growth ambitions.